Drugs / YHR1706
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03235362 | Aug → Sep 2017 | hyperlipidemia, type 2 diabetes mellitus | Yuhan Corporation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YHR1706 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03235362 ↗ |
| Route | Oral | “multiple oral doses of YHR1706” NCT03235362 ↗ |